



PRESS RELEASE

**Number of shares and voting rights of ADOCIA
as of April 30, 2017**

Lyon, France, May 15, 2017- 6pm CET - Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (*Autorité des Marchés Financiers*, or “AMF”) charter ADOCIA SA, a French *société anonyme* (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of April, 30th, 2017.

Month	Date	Total number of outstanding shares	Total number of theoretical voting rights (1)	Total number of exercisable voting rights (2)
April	04/30/2017	6 859 763	9 582 994	9 576 648

(1) *The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.*

(2) *The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement*

About ADOCIA

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's portfolio of injectable treatments for diabetes, featuring four clinical-stage products and six preclinical products, is among the largest and most differentiated of the industry.

The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.

Adocia's clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Human Glucagon), two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide), two combinations of insulin lispro with synergistic prandial hormones (BioChaperone Lispro Pramlintide and BioChaperone Lispro Exenatide), and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.

Adocia aims to deliver "Innovative medicine for everyone, everywhere."

To learn more about Adocia, please visit us at www.adocia.com



For more information please contact:

Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Ph. : +33 4 72 610 610	Adocia Press Relations Europe MC Services AG Raimund Gabriel adocia@mc-services.eu Ph. : +49 89 210 228 0	Adocia Investor Relations USA The Ruth Group Tram Bui tbui@theruthgroup.com Ph.: +1 646 536 7035
---	--	---